Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients.

Carbapenemase-producing Enterobacteriaceae antimicrobial resistance bacteria carriage infection prevention and control

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 22 6 2021
Statut: ppublish

Résumé

To determine the duration of carbapenemase-producing Enterobacteriaceae (CPE) carriage, we studied 21 CPE carriers for »1 year. Mean carriage duration was 86 days; probability of decolonization in 1 year was 98.5%, suggesting that CPE-carriers' status can be reviewed yearly. Prolonged carriage was associated with use of antimicrobial drugs.

Identifiants

pubmed: 32818397
doi: 10.3201/eid2609.190592
pmc: PMC7454053
doi:

Substances chimiques

Bacterial Proteins 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2182-2185

Subventions

Organisme : Wellcome Trust
ID : 106698/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006924/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R004536/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212630/Z/18/Z
Pays : United Kingdom

Références

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1135-1140
pubmed: 28096418
J Antimicrob Chemother. 2016 Oct;71(10):2729-39
pubmed: 27317444
Antimicrob Resist Infect Control. 2017 Nov 15;6:113
pubmed: 29163939
Commun Stat Simul Comput. 2017;46(9):7040-7061
pubmed: 29225407
Am J Infect Control. 2016 May 1;44(5):539-43
pubmed: 26899297
J Med Microbiol. 2013 Jul;62(Pt 7):1086-1088
pubmed: 23558141
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
Am J Infect Control. 2013 Mar;41(3):190-4
pubmed: 23449280

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH